. >> gmt w pharma. yep, i'm back, gwph.mentioned before, it's the only legitimate medical marijuana stock seeing that new york just approved medical marijuana. i like to think of it as the real play. this is a company that takes the chemical components and rigorously runs them to clinical trials to create actual drugs. medicinal marijuana may be league with legislation in the works for 13 others. while it's an industry in this country, few doctors want to write anyone a prescription for a joint. not just because the stuff is still illegal, where the federal government is concerned, but mostly because while smoking weed may help people who have cancer or glaucoma, it's simply not what most doctors would consider medicine. in this country prescription drugs need to be approved by the food & drug administration. without their approval, you have no idea what the risks or side effects might actually be or even the quantity or quality of the cannabis in each joint or dime bag or what have you? i remember when they called it a nic

our community, has been pharma promoted addictive painkillers?ackson tweets should not this read when hasn't big pharma....? hour, flipped, the internet has people diagnosing themselves and thus becoming hypo con democratics at the same time. he said this is a systemic for sale. all of the signs of this debate. >> definitely getting into that issue of whether it is a systemic failure. there has been a staggering search in prescription drug abuse and overdose deaths over the last 15 years and new lawsuits point the finger at pharmaceutical companies but not just any lawsuits. in claims reminencent on the war on tobacco, two california counties filed cases against five of the largest drug companies accusing them of causing the nation's drug epidemic by running deceptive advertising aimed at boosting drug sales. now chicago, after spending millions on er visits it blames on false advertising fuels addictions. are companies deliberately downplaying the danger of painkillers for profit? here to discuss this further out of los angeles is lisa guerian a

. >> host: what about the american medical association, american health association, pharma, are these groups active on the state level as well? >> guest: they are at it. >> host: and they don't all agree. >> guest: the tape different positions on these issues. but in terms of the pharmacy assistance programs, the interest groups work very at it in their adoption of these programs but the drug lobby was important in revising his programs. so once they are on the books at the new market expansion sola tie-dyed to make it more generous. we saw that in those programs. and then we saw the hot groups get behind expanding universal coverage because it fills my bad. in terms of managed-care is kind of a different coalition has that the regulation, not so much the cost of expenditure. >> host: virginia gray, what kind of money is being bent on the state level to lobby differ not ask of health care? you've got some different charts in here that show. >> guest: we didn't focus on the money because it was kind of a data problem at the state level and not all the states report that. there's only 4

astrazeneca, big cap pharma names.ou want to look at the biotech names because that will be the pipelines at some point in the future. this is the area now where the big pharma names are looking forward and saying this is somebody we have got to grab up for our pipeline to increase. >> what did you buy into as koe? >> i have added to lilly. i think there's plenty different names going to the up side from here. >> another big mover out of the arena conference pharmaceuticals. >> what we were looking at is ario pharmaceuticals. this was a stock that got shot up last october when there were concerns about arterial thrombosis and that caused the fda to suspend adding new participants to the trial. they just announced over the weekend the results of the trials. they seem to be positive. when we saw over three times the average daily call volume and they were buying those for about 15 cents. so those are making bullish bets that the stock trading just under $7 could be above $8 or $8.15 for june expiration. if you fall how h

biotech and pharma reporter with us. no more needles? >> that is the thought here with the new drug, approved on monday after rejected twice before. really a long road for mankind. finally getting onto the market. diabetes affects about 26 million americans. that's about 8% of the population with diabetes but analysts saying some of that stock volatility is due to safety concerns, that lane you mentioned, and also concerned about uptick. the safety side, the drug approved with a black box warning on the lane saying the drug shunt be used in chronic lung diseases like copd and asthma. the company will have to conduct a postmarketing study of the drug's effects on lung cancer. the uptake side, people may remember fizers a ex-zblub bra, thought could be a multibillion dollar drug, ended up pulling it from the market in 2007 when it wasn't used that much by parents there could be some concern there the next question, of course, for mankind, becomes can it find a big pharma partner to market the drug? i spoke with the company's cfo today. he

what i'm talking about is the perspective on research and development spending by big pharma. one of the key issues here, of course, when we talk about valeant and allergan. valeant's playbook being led by its ceo mike gerston saying r&d most of the money spent by big pharma is wasted. he saw this up close and when he got the opportunity to run a company like this his key focus is not necessarily stifling innovation but making sure innovation occurs well above the cost of capital to bring that innovation to bear. this morning valeant releases a report called its perspectives on r&d. why? of course as you know, allergan in its rejection of valeant's bid, cites its playbook, its complete cutting of r&d costs as a real negative and what it feels will ultimately be something that will cause a loss of value if it were actually to be acquired by valeant. as you might imagine, valeant disagrees. the points are larger points for the industry, which top ten companies spend about $68.5 billion in r&d right now. valeant will point out that is leveling out. that we're starting to see a le

no, mankind also rallying, and then there's it there's the amazing gw pharma. a push by piper jahvid ray might be able to use the epilepsy drug formulation to ultimately treat migraines and some form of autism. u.s. drug companies can't compete, because in this country owning mass quantities of marijuana is a felony. but gw is based in britain, and the fda is working with them, according to piper, to get this drugs into the hands of the desperately needed. british business, gw pharma cooks a takeover target of an american company looking to take advantage of the uk's lower tax rate. >>> here's the bottom line. the last day of the second quarter was a microcosm of 2014, lots of ways to win. somehow despite the odds, i think the third quarter may not be all that much different. let's go to tim in new york. >> caller: hey, jim, boo-yah, how is it going? >> not bad. how about you? >> caller: very well. irdm. >> no, man, no, that's no-go. we looked at that a long time ago, and liked it too much, and subsequent herb greenberg has does some great work for the reality

as well the companies include subsidiaries of johnson and johnson and have two of the largest pharma companies in the world joining me now to discuss the details of these lawsuits as well as the larger issue of addiction i'm joined now by our correspondent megan. thank you for coming on i mean thanks for having me on so record levels in the u.s. i mean this is just i'm saying the u.s. is one of two countries in the world with even director consumer advertising for pharmaceutical companies could that be a reason why we've seen such a massive rise in addiction there is absolutely the reason why two counties in california are saying that we are seeing this rise in addiction so just to kind of be some context and to put this into a bit of first person active the center for disease control is calling this the worst epidemic in the united states history when it comes to drugs so that is surprising thinking of back to tobacco and think you know of things that are much more dangerous than you would kind of associate cocaine and heroin and whatnot but just to give you some numbers two thousan

filed a lawsuit against the major manufacturers of these drugs naming johnson and johnson purdue pharma industries and zero health activists in their lawsuit orange county district attorney anthony recopy a spoke with over the phone about why he's pursuing these companies in particular. ok. last week chicago joined the fight filing a one hundred twenty six page lawsuit against those same manufacturers and accusing them of a twenty year long conspiracy to increase sales chicago's lawsuit alleges the companies downplayed the addictive qualities of the drugs using so-called front groups to publish biased reports about the benefits and extensive uses of opioids they're also accused of training doctors to turn to these harsh medications more frequently and targeting returning troops as a key demographic back in orange county recommit says one resident dies every other day from a prescription drug overdose and. require. them to tell the truth about. the pharmaceutical companies declined comment on the lawsuits but some say the blame shouldn't only rest on the shoulders of the manufacturers ab

built for business. >>> time for cramer and "stop trade". >> continue to abmazed at gw pharma.e, talks about the conference in chicago that occurred for epilepsy, they're saying it's not just for epileptics, for seizures for kidser it's remarkable. parents will do anything, all right. but this piece is very special, talks about -- gw pharma, the only pure play on marijuana, that you can't make in the country it's a class i felony but can make in england. talking about autism and migraines, the market size for the drug continues going higher and higher. it's a shorted stock. but the teslas, the netflix. from when i understand from the medical community the current treatment for epilepsy is so awful, it has so many side effects, versus success of this, that this one continues to work higher. remember, medical marijuana has not succeeded in the country because doctors don't like to prescribe it because it's not in uniform. another secret gem in the piece is that the fda working with gw pharma trying to figure out the offlabel uses, what to do. the fda would love for this -- for th

and uk pharma firm shire lays out its plan to reject takeover advances from u.s.pmi data has acted as a brake on european markets this morning. underwhelming french numbers show the country slipping into a deeper contraction. meanwhile, german manufacturing remains in growth, but the output increased at its weakest rate since september. now, as spain tries to steer itself out of the economic doldrums, the company plans to reduce its corporate tax rate, designed to stimulate investment and make spanish companies more competitive. earlier on the channel, u.s. billionaire wilbur ross said he'd like to see something similar in the u.s. >> i think it was fascinating that spain, as it's trying to emerge from its own crisis, has decided to cut corporate taxes. we'll see how well the eu likes that, but it's fascinating to me that they're going to take it from 30 down to 28 and then down to 25% in a couple of steps. i think that's the preferable direction for the u.s. to go. >> jay bryson obviously still with us. you were nodding there. do you want to comment on what he wa

. >>> meantime, we're getting a major announcement that's up next, plug meg on two pharma stories. >> that's right. next up, a stock that could jump to $100 a share or drop like a rock. it all depends on one single event. >> which -- more "power lunch" in two minutes. in today's market, a lot can happen in a second. with fidelity's guaranteed one-second trade execution, we route your order to up to 75 market centers to look for the best possible price, maybe even better than you expected. it's all part of our goal to execute your trade in one second. i'm derrick chan of fidelity investments. our one-second trade execution is one more innovative reason serious investors are choosing fidelity. call or click to open your fidelity account today. >>> welcome back. lu lu lemon is soareding on reports that he may even form a team to take the retailer private. they gave back much of their gains midmorning. they're up about 3.5%, simon, on today's session. >>> fire season is on in southern california. this blakz popped up yesterday in glendale in los angeles county. more than 200 firefighters

pharma firm abbvie, sending shares sharply higher in london. >>> are we getting closer to an agreementtsubishi and siemens tweeting their bid to the conglomerate putting $1.2 billion euros in additional cash on the table. >>> and the co-founder of twitter stone tells us valuations are nothing compared to the dotcom era. >> we are talking about hundreds of billions of dollars in the dotcom bust. now we're talking about ten. >> announcer: you're watching "worldwide exchange," bringing you business news from around the globe. >>> good morning, everyone. thank you so much for watching the show. this morning, it's friday. let's have a look at the futures. the dow, the s&p and the nasdaq are all seeing opening to the softer side. the dow is seen down by just a couple points. but this is after the s&p hit another record high in yesterday's trading session. yes, it was only up less than thee points, but it was another positive close and we'll take that. it was the defenses that led the gainers, so we'll see what happens today. let's have a look at the european markets, too, where we're seeing

under the new guidelines, big pharma tweet will now have to include all side effects and warnings printedthe product label. oh, come on! there's no way that pfizer could tell all their followers all the side effects for vooig i i haven just 140 characters. it has nine side effects including permanent damage to the penis, loss of sight, and loss of hearing. that is scary stuff. i for one do not know what i would do if my penis went blind and deaf. ( cheers and applause ). it would have to get a service dog. ( laughter ) well, as always, i am here to help the drug companies. there's a very simple way to treat your drug's complex side effects -- emojis. emojis can cover every possible side effect. for depression, just tweet a frowny face. risk of cardiac arrest, a broken heart. emojis can also tell people to avoid the drug if they're bipolar. or that clinical trials cause blindness in monkies. and most importantly, if there's a risk of gen till purpling. huge side effect fans here tonight. ( laughter ) next up, folks, summertime is upon us, and that means everyone is working to perfect their

kite pharma soared. they are studying a cancer solution offered up 7.5 million shares. look at where they ended today. investors snatched them up sending the stock up more than 70% to $29. >> kite flying high. there i said it. >>> shares of coors raised to $7 a sha 9 a share and they sited evaluation and improving fundamentals. that stock closed at 74.86, an increase of more than 2%. >>> it was a historic day for radioshack but not in a good way. that stock traded below $1 a share for the first time ever as investors continue to worry about the electron anything retailers struggles. the new york stock exchange can delist any stock if it closes below a dollar for 30 consecutive trading days. we're watching that one. shares were at 92 cents down more than 10.5% on radioshack. >>> and it looks like general electric is the winner in the battle for french government is backing ge's bid. it also said it's going to buy a 20% stake. to no avoil, alstom has to approve ge's bid. shares rose to $26.97. >>> owens corning say shares fall after the company lowered the outlook for the

clinical study results were used by novartis pharma in its advertising. shirahashi told nhk before his arrest that he didn't alter the data. authorities in tokyo raided the pharmaceutical company and the university in february after receiving a criminal complaint from the health ministry. they'll continue investigating to find out if university researchers were also aware of the suspected tampering. >>> an official from japan's foreign ministry has briefed the united states on last month's government talks with north korea. asian and oceanian affairs bureau chief junichi ihara was in washington to meet with glenn davies. he renewed his three-day talks in stockholm with north korean officials. he relayed pyongyang's promise to conduct a full investigation into the fate of japanese adductees and japan's agreement to ease some sanctions when the probe begins. he also commented on other north korean issues. >> translator: japan and the u.s. have reaffirmed the importance of coordinating policies with south korea, concerning north korea's nuclear and missile p

think gw pharma. they make nonlaced marijuana. >> the pure -- >> a pill. it here because it is a class one felony to do what they are doing. this is a british company. i can't stress enough how important it is for people with untreatable diseases to get rid of the pain. now actual treatment for kids with epilepsy. >> it could be a conversion if people want to buy it. >> yes. there is nothing. imagine something that stops seizures for a lot of people for 12 weeks? gw pharma is a real company doing real things with a marijuana dri tif. >> what's on "mad money" tonight? >> we have korn ferry, recruiting. and cynvenio. they may have a blood test to tell you if you have cancer. isn't that the holy grail of what we need in this country and the world? >> wow. >> exciting show. a lot going on. "might be" being the key word there. >> it's not public. i appreciate your tweet about coca-cola. i didn't like the idea of someone issuing a statement that says nlbo. i mean, lbo of apple -- >> there's plenty of money out there to finance it. even with war enat 9% with the

there are also lots of other pharma names that have been mentioned over the years in connection withfor shire. we don't know if any of those others are going to be making an approach as well. it is certainly something that will be on the mind of a lot of shire investors. will the be others who will come out of the woodwork besides abbvie offering more? >> the u.k. has a right to defend the science base that exists. do you think they will be concerned about shire? >> no. astrazeneca is a household name in a different way than shire. it is also not a u.k. domicile company for tax purposes. shire moved its own domicile to ireland. it has most operations in the u.s. national an emotive issue the way astrazeneca managed to become. >> doesn't have huge forms of dollars sitting offshore that it wants to spend? is that the main reason? >> if you speak to people on the -- there is great sensitivity around being accused of doing something just for tax purposes. clearly, it does not hurt. all of these companies have lots of cash. they'll want to buy something instead of paying 35% corporation t

i think the specialty pharmaed by has one that's consolidated and i don't think that pfizer/astrazenecabeen written on that one either. >> to be continued. thanks for joining us on the deal. barbara ryan, a managing director at fti consulting. david, you're focused on where the next deal's going to come from. >> interesting listening to barbara. i did want to point out, medtronic shares turned down. there is some question whether the accretion is going to be quite as much and as quick as perhaps had been hoped when it was read in the press release as opposed to discussed on the conference call. and i also wanted to note, our other big deal if ecan bring it it up, level 3, lvlt, that has turned sharply lower, not sure why at this point. one of the things typical in this robust environment for mergers and acquisitions the stock of acquiring company has gone up. that has dramatically moved lower at level 3, one of the bigger deal, the acquisition of time warner telecom, wanted to note both. >> questions about the deals. up next, more on the technical issues at target that shut down some ch

international with maybe andrey pharma. now russia is demanding an investigation over claims that the ukrainian army you spoke for response in the eastern city of slavyansk residents there claim they were awakened by what they claimed were fire bombs being dropped these weapons a ban by the u.n. in kiev denies their use is what locals a say you don't feel what. we all saw what happened here yesterday they used rocket launchers as well as incendiary bombs against us the ground was on fire the ground burned by itself it burned for about forty minutes. and it's starting from ten am everyone every man has said a sore throat and scotland all the time i think this is because it will burning i think will feel the true consequences later there are still a lot of people out here it's a lot of children we haven't managed to get out yet. but we spoke to a former british army and intelligence officer who's recently returned from ukraine he told us that the attacks bears signs of phosphorus weapons. i've seen the video i've looked at it

many of the large pharma companies over the last 25 years have left this space.sivextra's a powerful drug, an iv and oral agent, both fight against infections including mrsa. with all the pressure on costs in the health care system, having an oral option, so folks who have these very serious infections potentially don't have to go into the hospital, that they can be treated as out-patients we think is a big advance. >> you know, i was intrigued when reading about the number of companies that have left the antibiotic space. why is that? are the margins not good? too much competition? what's going on there? >> it's a couple of things, i think, bill. primarily, it's economic. you know, sivextro's a great example. the phase three data, the approval for this drug is for a six-day course. and yet, the costs and risks associated with developing new antibiotics are much like they are for chronic care meds. there are some differences, but you know, you look at total cost, it looks very similar. >> okay. >> so, if you're a large pharma company and you have a choice of bett

what we have seen in the pharma these block buster drugs other ones getting interest. you mentioned they have gone public. does that mean that they have given up on the board and now they are going to try to go direct to shareholders? way this is played out is actually not dissimilar to what happened with pfizer and astrazeneca. that was a bear hug approach where pfizer to go very public with exactly what it offered to astrazeneca's shareholders and that had the intention of getting shareholders to pressure management to come to the table. is adjusting strategy. -- it is an interesting strategy. it did not work. as a result, pfizer has gone away. we will have to see what happens over the next 28 days in which we can see with the result of the announcement is. >> there is a tax motivation. we'venot the first time talked about irish businesses being bought for this reason. do we think that governments in europe will get active over their businesses being bought off with this as a motivation? >> i think governments in europe actually tend to benefit from these decisions.

because by becoming an independent company it allowed them to acquire special drug maker cadence pharmaand then cresse corp, for 5.6 billion. when it was part of covidien, it couldn't have countens those deals. it wanted less exposure. but as two separate companies, both businesses can do what's best for themselves. as i mentioned earlier, there's another aspect to this deal, the change of address factor. or what's known as tax inversion. medtronics an american company. in the u.s. corporate tax rates are very high. covidien is based in ireland, a torte corporate tax haven. so by acquiring covidien, medtronic will be able to relocate its headquarters and change where its domiciled, in order to benefit, but medtronic didn't just bike it because it was an attractive takeover. no, what's happened in the mel device space looks like what we've been seeing in the grocery store aisle, where food companies are aggressively merging with each other to take market share. the same is true in the medical device space. by acquiring covidien medtronic will be able to accelerate its growth and gain sha

we'll consider investing, energy, pharma, or pinpoint russia or a region like asia. i'll explain the pros and cons and whether the risk is worth the reward. you'd like to jump on the bandwagon and like to make money out the air b&b but you find the idea of a stranger in your bed is creepy. >> on tech know. >> that is immense... >> there a misunderstood... ...vital part of the ecosystem >> ...is a tiger shark... ...first one of the expodition >> can they be saved? >> sharks don't eat people... >> tech know, every saturday go where science meets humanity. >> this is some of the best driving i've every done, even though i can't see. >> tech know. >> we're here in the vortex. only on al jazeera america. >> air b and b, the website that let's people rent out room on their sofa or their house is valued at $10 billion. they raised $5 million since their last round of funding, and investors are not the only ones that want a piece of the action. savvy entrepreneurs, around the world, avertable ecosystem of company that want to cash in on the frenzy. so you have decided to ren

tw pharma one of my favorite specks. i see the stock knocked down. that being on it is an opportunity. opportunity. just for you, i'm >> narrator: in this episode of "american greed"... kwame kilpatrick... the youngest mayor in the history of detroit. >> i was elected mayor at age 31 years old because i dared mighty things for the citizens of my city. >> there were many people who believed that he was the next generation of leadership. >> narrator: a leader who many hope will bring the swagger back to the motor city. >> he was the hip-hop mayor. he was hanging out with the athletes. >> narrator: but his outrageous temptations lead to unimaginable corruption. >> from the day he walked in, this was about, "how can i make kwame kilpatrick, my family, and my friends richer?" >> the mayor had $840,000 in unexplained cash in his pe

we'll consider investing, energy, pharma, or pinpoint russia or a region like asia. i'll explain the pros and cons and whether the risk is worth the reward. you'd like to jump on the bandwagon and like to make money out the air b&b but you find the idea of a stranger in your bed is creepy. i hear you. savvy entrepreneurs have tape a different approach. i'll show you after the break. >> air b and b, the website that let's people rent out room on their sofa or their house is valued at $10 billion. they raised $5 million since their last round of funding, and investors are not the only ones that want a piece of the action. savvy entrepreneurs, around the world, avertable ecosystem of company that want to cash in on the frenzy. so you have decided to rent out your apartment on-air b and b and shoot off to the tropics for vacation. congrats, just a few small details. how will you org the key exchange? what happens if a pipe burst if you're gone? how do thank you handle the gross factor of coming back to an apartment lived in by strangers? fear not, new startups aimed to s

our biotech and pharma meg turrell is there. >> i'm here with the ceo of insight.joining us. >> thank you. >> we saw your stock fall earlier and when you presented some data just now it's really coming back. seen a pop. explain your drug on the market and why that drug is looking so good to investors. >> what's happened this year is there's a lot of development coming from inside programs in a lot of different types so we have jackified in pv which means we'll be coming tomorrow and date. recall many this is happening, a new field of research, a look at onco inflammation and as we said we had very important innovat n innovation, the innknow field i combination with other techniques. >> this partnering strategy really seems to be core to insight. tell us why you're partnered with so many other companies. >> i think it's really about a belief that the science will drive our success and the company is based on that, that if we have good science, good product, obviously we'll ultimately be successful, and what's happening now in the field of treatment of cancer is that

like celgene is one of the four horseman of the big pharma apock lips in "get rich carefully."i have enough things on the fingers to interest you? okay. he notes -- ponsy notes that regeneron also got slammed. this fell off 20%. you know, if we blew this up, it would look like -- all right? and although given how hard the stock has been rallying going into the peak, you know notice that the pull back barely registers. this is like a blip in the long march higher. he pointed out that it bottomed when the stock tested the bullish trend line that goes all the way back to 2012. these things kind of work out on the chart. the same regeneron ran up the strong store support at at the 274 level, it held that level. when it was down there, i was told that it was okay, even though the fundamentalists told me it was over. now it's rebounded back and crucially for ponsy it looks like it's about to flash the same bullish crossover like celgene. when that happens regeneron will be headed much higher. oh, man, let's look at one that's left for dead. smaller biotech. totally hammered. i'm talk

. >> pharma sick cyclics is good. gilead should be better given the last quarter it was off the carts ridiculous. this is a $100 stock. we mentioned celgene should push up to that 175 level months ago. so there are names that still work in this space regardless of what i think about the broader market. >> let's get a broader flash with dom shue. >> it is moving. vertex up 40%. bristol-myers a much larger company in the after hours trade after it announced it halted a late-staged trial for skin cancer drug because of positive results. now, this particular drug represents a product of their immunooncology department. >> that is the department that tries to remedy cancer by using the bid's own defenses and immune systems. so this is a promising hope-filled part of the market for biopharmaceuticals rather than using radiation or xhalts for cancer, which has been the main stay. this particular stock is now moving because of this news, melanoma, skin cancer. this drug halted positive results. that's why it's moving higherch

the catalyst could be news about event you're predicting if you're dealing with pharma stocks or biotechslysts when the companies release their clinical trial data about important drugs in development or the fda decides whether or not to give -- to approve a given treatment. these are data points to send the stocks soaring higher if they go your way. so when you make a trade going into it you need to know there's a moment to buy before the catalyst and a moment most importantly that people seem to get wrong to -- >> sell sell sell. >> after the catalyst happens. sometimes your trades won't work, the event you're waiting for won't happen or the data point you're expecting turns out to be less positive than you expected. either way, when you buy a stock as a trade, it has a limited she will life. only a brief window you want to own it. once the window passes you must sell sell sell. >> hopefully you'll turn the right catalyst and be right about it and rack up nice gains if that happens, there's no point in sticking around. ring the register, lock in your profits. if it turns out to be wrong

liz: does this mean he want to get rid of things like tax incentives for big oil, big pharma, cut inhe corporate tax rate, what can we expect from him? we want to know what businesses can expect. >> he seems more libertarian than eric cantor does. he had close relations, very close business people, but we really don't know that much of dave brat yet. which is why it is a surprise. the internal issues 34% lead for eric cantor going into this. i think people are first become acquainted with dave brat basically today thanks to his victory. liz: and now we know the polls are not very reliable. >> or his staff is not very good. liz: you speak to wall street, is wall street quaking in their boots? >> eric cantor is not some lefty, some liberal do-gooder, this is a guy who is pretty conservative tea party people generally if you ask them about his basic stance he would line up okay with the tea party. what you had, i believe, is a degree of demagoguery by dave brat. what he did was tie this guy, make them to be some guy that's first allegiance is to wall street because eric cantor happens t

hour, it's a $60 billion business and growing and it's turning into a major battle ground for big pharmawhat's at stake and the stocks that stand to win? the crisis in iraq, raising questions about whether the u.s. can really be energy independent. results of a new report casting some doubt on that one. and american contractors stuck in iraq. what the major u.s. defense companies are doing. more "halftime" though after this quick break. huh...fifteen minutes could save you fifteen percent or more on car insurance. mmmhmmm...everybody knows that. well, did you know that old macdonald was a really bad speller? your word is...cow. cow. cow. c...o...w... ...e...i...e...i...o. [buzzer] dangnabbit. geico. fifteen minutes could save you...well, you know. seeing the world in reverse, and i loved every minute of it. but then you grow up and there's no going back. but it's okay, it's just a new kind of adventure. and really, who wants to look backwards when you can look forward? >>> everyone talks about the most loved stocks on wall street. actually, you know what? first i want to show you these p

born out of a place of financial engineering and that's what's really matters in the biotech and pharmainvestors want to see true innovation. so i don't see -- >> that's a no. >> we've meh, carter wirth, a competing adjective from a technical perspective? >> things like blah do come to mind. it's not exciting situation. in fact it's worse than that, but let's look at three charts. the long-term chart is very telling, in the sense we know stocked peaked in '99 or 2000, and then made any highs in '07. pfizer never did that. pfizer kept going down. the recent bounce with this bull market, all it did is return it to the retracement level, where it's now started to struggle. not good action, and then of course the relative. relative strength matters, and no reason to put money here. >> on the same page there for pfizer. thank you for joining us. if you want more talking numbers check out the online edition in part with yahoo finance. >> the host of that show is really handsome. >> who is he? >> my evil twin tloo up next retail founders gone wild, the big fight to the top of two iconic clothi

the big pharma partner with cicada.ave experience in diabetes, talking to a lot of the same doctors there. the combination of drugs that major of contrave and includes an antidepressant that's already approved. also looking forward to an ipo that could price this year from a company call zakgen, so really looking at how this is changing. >> a lot of cross-currents. there is that skepticism. let's go to jon fortt for a developing story. >> thanks, tyler. interesting fib facebook and ceo zhukker berg are being accused of wasting corporate assets. a shareholder has filed a suit say nonemployees members are paid an average of $461,000 last year, well above industry averages, but google pays its directors right around that amount as well. the suit asks excessive compensation to be recouped and restrictions be imposed on the board's ability to pay its members. a facebook spokesperson tells the nbc that the lawsuit is without merit and we will defend ourselves vigorously. that's a quote. >> jon, thank you. >>> the fight agains

big pharma bribery investigation has taken a dark new twist with the emergence of a sex tape.candal-ridden, glaxosmithkline received a video of their most senior manager for the country getting intimate with a mistress in his shanghai apartment. the drugmaker's china business has been already badly damaged after a strange string of allegations involving kickbacks to doctors. >>> in scotland, officials are battling to get a local delicacy on dinner plates. haggis. which is basically a bunch sheep parts stuffed in other sheep parts. oh. was originally band and with good reason back in the united states back in the 0's. now scotland wants the band lifted saying many americans would like to have access to it. obviously! maybe in order to celebrate their scottish heritage but i'm not scottish and i'm not eating that. >>> coming up, did the franchise kill the movie star? how the biggest summer blockbuster may push hollywood's brightest to the age of extinction. >>> social experiment gone very, very wrong. facebook messing with user's emotions and making no friends along the way. do